CorVel (CRVL)
Market Price (9/24/2026): $73.34 | Market Cap: $3.7 BilSector: Health Care | Industry: Health Care Services
CorVel (CRVL)
Market Price (9/24/2026): $73.34Market Cap: $3.7 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 41% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -63% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x, P/EPrice/Earnings or Price/(Net Income) is 32x Key risksCRVL key risks include [1] rapid AI innovation threatening its established business model and competitive position, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 41% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -63% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x, P/EPrice/Earnings or Price/(Net Income) is 32x |
| Key risksCRVL key risks include [1] rapid AI innovation threatening its established business model and competitive position, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/14/2026
CorVel (CRVL) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Robust Financial Performance in Fiscal Q1 2027. CorVel reported strong results for its fiscal first quarter ended June 30, 2026, which were announced on August 5, 2026. The company's revenues increased by approximately 11% year-over-year to $259.9 million, and diluted earnings per share (EPS) rose by 22% to $0.63 from $0.52 in the prior-year quarter. Gross profit also saw a significant increase to $67.8 million, demonstrating a 26% margin, compared to $56.8 million in the previous year. This positive earnings report contributed to a 5.87% gain in CRVL's stock on the day of the announcement. These results were primarily driven by increased claims volume, new customer acquisitions, and growth in the payment integrity business.
2. Strategic Leadership Transition and Continued Investment in Technology. Effective July 1, 2026, Sarah Scott was appointed CEO and President, succeeding Michael G. Combs, who transitioned to Executive Chair, signaling a planned and experienced leadership change. Concurrently, CorVel continued its strategic investments in technology, particularly in artificial intelligence (AI) and automation, to enhance its service offerings. The company's health division, CERIS, experienced strong demand for its integrated payment accuracy and cost management platforms, securing multiple large payer sales and expanding payment integrity capabilities through new client implementations, which provides increased revenue visibility. This focus on innovation and service expansion was also recognized with CorVel being named a 2026 PropertyCasualty360 Insurance Luminaries winner for Excellence in Claims Management.
Show more
CorVel (CRVL) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Robust Financial Performance in Fiscal Q1 2027. CorVel reported strong results for its fiscal first quarter ended June 30, 2026, which were announced on August 5, 2026. The company's revenues increased by approximately 11% year-over-year to $259.9 million, and diluted earnings per share (EPS) rose by 22% to $0.63 from $0.52 in the prior-year quarter. Gross profit also saw a significant increase to $67.8 million, demonstrating a 26% margin, compared to $56.8 million in the previous year. This positive earnings report contributed to a 5.87% gain in CRVL's stock on the day of the announcement. These results were primarily driven by increased claims volume, new customer acquisitions, and growth in the payment integrity business.
2. Strategic Leadership Transition and Continued Investment in Technology. Effective July 1, 2026, Sarah Scott was appointed CEO and President, succeeding Michael G. Combs, who transitioned to Executive Chair, signaling a planned and experienced leadership change. Concurrently, CorVel continued its strategic investments in technology, particularly in artificial intelligence (AI) and automation, to enhance its service offerings. The company's health division, CERIS, experienced strong demand for its integrated payment accuracy and cost management platforms, securing multiple large payer sales and expanding payment integrity capabilities through new client implementations, which provides increased revenue visibility. This focus on innovation and service expansion was also recognized with CorVel being named a 2026 PropertyCasualty360 Insurance Luminaries winner for Excellence in Claims Management.
Show more
Updated on 9/14/2026
CorVel (CRVL) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Robust Financial Performance in Fiscal Q1 2027. CorVel reported strong results for its fiscal first quarter ended June 30, 2026, which were announced on August 5, 2026. The company's revenues increased by approximately 11% year-over-year to $259.9 million, and diluted earnings per share (EPS) rose by 22% to $0.63 from $0.52 in the prior-year quarter. Gross profit also saw a significant increase to $67.8 million, demonstrating a 26% margin, compared to $56.8 million in the previous year. This positive earnings report contributed to a 5.87% gain in CRVL's stock on the day of the announcement. These results were primarily driven by increased claims volume, new customer acquisitions, and growth in the payment integrity business.
2. Strategic Leadership Transition and Continued Investment in Technology. Effective July 1, 2026, Sarah Scott was appointed CEO and President, succeeding Michael G. Combs, who transitioned to Executive Chair, signaling a planned and experienced leadership change. Concurrently, CorVel continued its strategic investments in technology, particularly in artificial intelligence (AI) and automation, to enhance its service offerings. The company's health division, CERIS, experienced strong demand for its integrated payment accuracy and cost management platforms, securing multiple large payer sales and expanding payment integrity capabilities through new client implementations, which provides increased revenue visibility. This focus on innovation and service expansion was also recognized with CorVel being named a 2026 PropertyCasualty360 Insurance Luminaries winner for Excellence in Claims Management.
3. Share Repurchase Program and Strong Balance Sheet. CorVel actively enhanced shareholder value through its ongoing share repurchase program. During fiscal Q1 2027 (ended June 30, 2026), the company repurchased $21.8 million of common stock. This followed a repurchase of $20.1 million of stock in the preceding fiscal Q4 2026. The company maintained a strong financial position, exiting fiscal Q1 2027 with $255.9 million in cash and cash equivalents and no borrowings, providing financial flexibility and stability.
4. Positive Analyst Sentiment and Institutional Investor Interest. The period saw an improvement in analyst ratings for CorVel. Wall Street Zen upgraded CorVel's stock from a "hold" to a "buy" rating on May 30, 2026, just before the specified period. Furthermore, Weiss Ratings upgraded the stock from a "hold (c-)" to a "hold (c)" rating on September 1, 2026. This positive sentiment was mirrored by increased institutional investor activity, with several firms initiating or raising their stakes. Notably, Algert Global LLC increased its position by 67.0% in fiscal Q2, holding shares valued at $23,971,000. The Manufacturers Life Insurance Company also acquired a new stake worth approximately $931,000 during the same period.
Show less
CorVel (CRVL) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Robust Financial Performance in Fiscal Q1 2027. CorVel reported strong results for its fiscal first quarter ended June 30, 2026, which were announced on August 5, 2026. The company's revenues increased by approximately 11% year-over-year to $259.9 million, and diluted earnings per share (EPS) rose by 22% to $0.63 from $0.52 in the prior-year quarter. Gross profit also saw a significant increase to $67.8 million, demonstrating a 26% margin, compared to $56.8 million in the previous year. This positive earnings report contributed to a 5.87% gain in CRVL's stock on the day of the announcement. These results were primarily driven by increased claims volume, new customer acquisitions, and growth in the payment integrity business.
2. Strategic Leadership Transition and Continued Investment in Technology. Effective July 1, 2026, Sarah Scott was appointed CEO and President, succeeding Michael G. Combs, who transitioned to Executive Chair, signaling a planned and experienced leadership change. Concurrently, CorVel continued its strategic investments in technology, particularly in artificial intelligence (AI) and automation, to enhance its service offerings. The company's health division, CERIS, experienced strong demand for its integrated payment accuracy and cost management platforms, securing multiple large payer sales and expanding payment integrity capabilities through new client implementations, which provides increased revenue visibility. This focus on innovation and service expansion was also recognized with CorVel being named a 2026 PropertyCasualty360 Insurance Luminaries winner for Excellence in Claims Management.
3. Share Repurchase Program and Strong Balance Sheet. CorVel actively enhanced shareholder value through its ongoing share repurchase program. During fiscal Q1 2027 (ended June 30, 2026), the company repurchased $21.8 million of common stock. This followed a repurchase of $20.1 million of stock in the preceding fiscal Q4 2026. The company maintained a strong financial position, exiting fiscal Q1 2027 with $255.9 million in cash and cash equivalents and no borrowings, providing financial flexibility and stability.
4. Positive Analyst Sentiment and Institutional Investor Interest. The period saw an improvement in analyst ratings for CorVel. Wall Street Zen upgraded CorVel's stock from a "hold" to a "buy" rating on May 30, 2026, just before the specified period. Furthermore, Weiss Ratings upgraded the stock from a "hold (c-)" to a "hold (c)" rating on September 1, 2026. This positive sentiment was mirrored by increased institutional investor activity, with several firms initiating or raising their stakes. Notably, Algert Global LLC increased its position by 67.0% in fiscal Q2, holding shares valued at $23,971,000. The Manufacturers Life Insurance Company also acquired a new stake worth approximately $931,000 during the same period.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 18.7% change in CRVL stock from 5/31/2026 to 9/23/2026 was primarily driven by a 12.8% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 61.75 | 73.30 | 18.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 959 | 984 | 2.6% |
| Net Income Margin (%) | 11.5% | 11.7% | 1.8% |
| P/E Multiple | 28.6 | 32.3 | 12.8% |
| Shares Outstanding (Mil) | 51 | 51 | 0.7% |
| Cumulative Contribution | 18.7% |
Market Drivers
5/31/2026 to 9/23/2026| Return | Correlation | |
|---|---|---|
| CRVL | 18.7% | |
| Market (SPY) | 1.8% | -21.6% |
| Sector (XLV) | 13.4% | 48.2% |
Fundamental Drivers
The 42.1% change in CRVL stock from 2/28/2026 to 9/23/2026 was primarily driven by a 29.0% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 51.58 | 73.30 | 42.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 941 | 984 | 4.5% |
| Net Income Margin (%) | 11.2% | 11.7% | 4.4% |
| P/E Multiple | 25.0 | 32.3 | 29.0% |
| Shares Outstanding (Mil) | 51 | 51 | 1.0% |
| Cumulative Contribution | 42.1% |
Market Drivers
2/28/2026 to 9/23/2026| Return | Correlation | |
|---|---|---|
| CRVL | 42.1% | |
| Market (SPY) | 12.5% | -11.7% |
| Sector (XLV) | 6.3% | 25.3% |
Fundamental Drivers
The -17.7% change in CRVL stock from 8/31/2025 to 9/23/2026 was primarily driven by a -28.8% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 89.05 | 73.30 | -17.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 919 | 984 | 7.1% |
| Net Income Margin (%) | 11.0% | 11.7% | 6.8% |
| P/E Multiple | 45.4 | 32.3 | -28.8% |
| Shares Outstanding (Mil) | 51 | 51 | 1.1% |
| Cumulative Contribution | -17.7% |
Market Drivers
8/31/2025 to 9/23/2026| Return | Correlation | |
|---|---|---|
| CRVL | -17.7% | |
| Market (SPY) | 20.3% | 0.7% |
| Sector (XLV) | 25.0% | 22.5% |
Fundamental Drivers
The 1.6% change in CRVL stock from 8/31/2023 to 9/23/2026 was primarily driven by a 34.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 72.15 | 73.30 | 1.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 733 | 984 | 34.3% |
| Net Income Margin (%) | 9.5% | 11.7% | 23.6% |
| P/E Multiple | 53.4 | 32.3 | -39.5% |
| Shares Outstanding (Mil) | 51 | 51 | 1.2% |
| Cumulative Contribution | 1.6% |
Market Drivers
8/31/2023 to 9/23/2026| Return | Correlation | |
|---|---|---|
| CRVL | 1.6% | |
| Market (SPY) | 77.0% | 26.6% |
| Sector (XLV) | 33.2% | 30.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CRVL Return | 96% | -30% | 70% | 35% | -39% | 9% | 108% |
| Peers Return | 29% | 11% | 30% | -2% | -9% | 8% | 80% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| CRVL Win Rate | 83% | 25% | 67% | 67% | 33% | 78% | |
| Peers Win Rate | 55% | 57% | 48% | 55% | 58% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| CRVL Max Drawdown | -12% | -37% | -16% | -17% | -48% | -36% | |
| Peers Max Drawdown | -19% | -20% | -18% | -27% | -37% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AJG, CRD-A, CI, UNH, ELV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/23/2026 (YTD)
How Low Can It Go
| Event | CRVL | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -11.3% | -9.5% |
| % Gain to Breakeven | 12.8% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -37.1% | -24.5% |
| % Gain to Breakeven | 59.0% | 32.4% |
| Time to Breakeven | 328 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.4% | -33.7% |
| % Gain to Breakeven | 67.8% | 50.9% |
| Time to Breakeven | 112 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -18.9% | -3.7% |
| % Gain to Breakeven | 23.4% | 3.9% |
| Time to Breakeven | 86 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -11.4% | -12.2% |
| % Gain to Breakeven | 12.9% | 13.9% |
| Time to Breakeven | 20 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -27.5% | -6.8% |
| % Gain to Breakeven | 37.8% | 7.3% |
| Time to Breakeven | 108 days | 15 days |
In The Past
CorVel's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CRVL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -37.1% | -24.5% |
| % Gain to Breakeven | 59.0% | 32.4% |
| Time to Breakeven | 328 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.4% | -33.7% |
| % Gain to Breakeven | 67.8% | 50.9% |
| Time to Breakeven | 112 days | 140 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -27.5% | -6.8% |
| % Gain to Breakeven | 37.8% | 7.3% |
| Time to Breakeven | 108 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -22.0% | -17.9% |
| % Gain to Breakeven | 28.2% | 21.8% |
| Time to Breakeven | 67 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -33.1% | -53.4% |
| % Gain to Breakeven | 49.4% | 114.4% |
| Time to Breakeven | 105 days | 1085 days |
In The Past
CorVel's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CorVel (CRVL)
CorVel Corporation (CRVL) provides technology-driven solutions aimed at helping organizations manage medical costs and monitor the quality of care for various healthcare claims. The company primarily focuses on workers' compensation, auto liability, general liability, and health claims, applying advanced technologies like artificial intelligence, machine learning, and natural language processing to enhance the management of care episodes and related expenditures. CorVel's services are designed to support a wide range of clients, including employers, third-party administrators (TPAs), insurance companies, and government agencies.
CorVel's comprehensive offerings are broadly categorized into network solutions and patient management services. Network solutions encompass automated medical fee auditing, preferred provider organization (PPO) management, retrospective utilization review, facility claim review, and pharmacy services, all geared towards cost containment and efficiency. Patient management services include claims management, case management, 24/7 nurse triage, utilization management, and vocational rehabilitation, focusing on guiding patients through their care and recovery. The company also processes claims for self-insured payors within the property and casualty insurance sector, providing a holistic approach to claim resolution and cost control.
AI Analysis | Feedback
Here are two brief analogies for CorVel:
Stripe for managing complex medical and injury claims. CorVel uses technology to simplify and optimize the intricate processes of managing healthcare claims for businesses, similar to how Stripe streamlines payment processing.
Coupa for managing healthcare costs related to workers' compensation and other claims. CorVel helps organizations efficiently control and reduce medical expenditures arising from various types of claims, much like Coupa helps businesses manage overall spending.
AI Analysis | Feedback
CorVel Corporation (CRVL) Major Products/Services
-
Network Solutions Services
- Medical Bill Review & Auditing: Automated review and auditing of medical bills for compliance, accuracy, and cost management across various claim types.
- Preferred Provider Organization (PPO) Management: Services for developing and managing networks of healthcare providers and their associated reimbursement processes.
- Pharmacy Benefit Management: Comprehensive management of prescription drug claims and costs.
- Independent Medical Examinations (IMEs): Provision of objective medical evaluations by independent physicians to assess injuries and treatment.
- Clearinghouse & Medicare Solutions: Services facilitating the electronic exchange of healthcare claims and addressing specific Medicare compliance and resolution needs.
- Retrospective Utilization Review: Assessment of the medical necessity and appropriateness of healthcare services that have already been provided.
-
Patient Management Services
- Claims Management: End-to-end administration and processing of various healthcare claims for payors.
- Case Management: Personalized coordination of healthcare services for individuals with complex medical conditions or significant injuries.
- 24/7 Nurse Triage: Round-the-clock medical advice, assessment, and guidance provided by registered nurses.
- Utilization Management: Review of healthcare services for medical necessity and appropriateness before, during, or after treatment.
- Vocational Rehabilitation: Programs and support designed to assist injured or ill individuals in returning to suitable employment.
- Life Care Planning: Development of comprehensive long-term care strategies for individuals with catastrophic injuries or chronic health conditions.
- Property & Casualty Claims Processing: Specialized services for processing property and casualty claims, particularly for self-insured payors.
AI Analysis | Feedback
CorVel Corporation (CRVL) primarily provides its workers' compensation, auto, liability, and health solutions to other companies and organizations. Based on the provided background information, its major customers are broadly categorized as:
- Employers
- Third Party Administrators (TPAs)
- Insurance Companies
- Government Agencies
The background information does not provide specific names of individual customer companies or their public symbols.
AI Analysis | Feedback
null
AI Analysis | Feedback
Michael G. Combs President & CEO, Chairman
Michael G. Combs was appointed CEO in January 2019 and has served as President since April 2017. He previously held the position of Chief Information Officer from April 2015 to April 2017. Mr. Combs began his career at CorVel as a software engineer in October 1991 and has been with the company for over 27 years, with prior roles including Vice President of Bill Review Development and Deputy Chief Information Officer. In November 2024, he also succeeded founder V. Gordon Clemons as Chairman.
Brian Nichols Chief Financial Officer
Brian Nichols was appointed Chief Financial Officer of CorVel Corporation on September 10, 2025. He has been with the company for 15 years, having most recently served as Vice President, Network Services in 2025. His previous positions at CorVel include Vice President, Network Solutions (2016-2025), Director, Network Solutions (2014-2016), Network Solutions Manager (2011-2014), and Patient Care Coordinator (2010-2011). Mr. Nichols holds a Master of Business Administration from Anderson University and a Bachelor of Science in Management from Indiana Wesleyan University.
Mark E. Bertels Executive Vice President, Risk Management Services
Mark E. Bertels serves as the Executive Vice President of Risk Management Services for CorVel Corporation.
Maxim Shishin Chief Information Officer
Maxim Shishin is the Chief Information Officer at CorVel Corporation. Prior to his current role, he was a Software Developer at In Think Corporation and served as Vice President of Information Systems at CorVel. Mr. Shishin studied at National Research Nuclear University MEPhI and Portland State University.
Sarah Scott Executive Vice President of Product
Sarah Scott was promoted to Executive Vice President of Product on February 13, 2025. She has a 25-year tenure with CorVel, starting as a Nurse Case Manager and previously holding the role of Vice President of Network Solutions. In her former role, she was responsible for overseeing key practice areas such as pharmacy management, network management, ancillary services, independent medical examinations (IME), and professional review.
AI Analysis | Feedback
CorVel Corporation (CRVL) faces several key risks to its business operations and financial performance.
- Medical Cost Inflation and Pricing Pressure: The company's business model, which focuses on managing medical costs for healthcare claims, is significantly impacted by medical cost inflation, directly increasing the liabilities CorVel must reserve for its claims. Furthermore, persistent political pressure to reduce employer costs often leads to lower workers' compensation premium rates, which can restrict CorVel's revenue growth, particularly within its Network Solutions segment. The competitive nature of the healthcare cost containment industry, coupled with economic pressures for cost savings and legislative reforms, also subjects CorVel to pricing pressures. Should CorVel fail to meet payment deadlines, there is a risk that healthcare providers may revert to charging full, undiscounted rates, posing a notable operational risk.
- Labor Shortages and Execution on Technology Investments: CorVel faces challenges due to a shrinking supply of specialist labor in the industry, even as demand potentially increases. The company is heavily investing in technology, including artificial intelligence (AI), to enhance its operations and manage healthcare costs. A significant risk lies in the possibility that the anticipated benefits of these AI investments may not be fully realized. If AI integration does not effectively increase caseload capacity or improve efficiency, the costs associated with attracting and retaining qualified personnel could escalate without a corresponding operational improvement.
- Regulatory and Legislative Changes: The complex and evolving regulatory and political environment in the workers' compensation and healthcare industries presents a substantial risk. Changes in state-level policies regarding reimbursement rates or utilization review rules can materially affect CorVel's fee-for-service and savings-based revenue streams. Additionally, the expansion of statutory presumptions, which shift the burden of proof away from employers or third-party administrators, can increase claim complexity and potential liability exposure for the company. Broad legislative and administrative changes in the healthcare and insurance sectors could also adversely impact CorVel's business, results of operations, and financial condition.
AI Analysis | Feedback
null
AI Analysis | Feedback
CorVel Corporation (CRVL) operates in several large addressable markets within the United States, providing workers' compensation, auto, liability, and health solutions.
Addressable Markets for CorVel's Main Products and Services (U.S. Region)
- Workers' Compensation Solutions: The market size for Workers' Compensation Insurance in the United States is projected to be $51.2 billion in 2026. In 2024, the total direct premiums written in the workers' compensation market were $57.48 billion. For private carriers, the net written premium was $41.6 billion in 2024.
- Auto & Liability Solutions: The U.S. motor insurance market size is projected to be USD 532.45 billion in 2026 and is forecast to reach USD 826.30 billion by 2031. Liability coverage accounted for 64.39% of the U.S. motor insurance market share in 2025. More broadly, the U.S. liability insurance market size was estimated at USD 107.40 billion in 2024 and is projected to reach around USD 196.39 billion by 2034.
- Healthcare Claims Management and Medical Claims Processing: The U.S. healthcare claims management market generated USD 7,683.8 million in revenue in 2022 and is expected to reach USD 37,558.2 million by 2030. In 2025, the U.S. healthcare claims management market was valued at USD 7.18 billion and is expected to reach USD 12.48 billion by 2035. The medical claims processing services market in the U.S. was $5.6 billion in 2024 and is projected to be $5.7 billion in 2025.
- Utilization Management Solutions: The U.S. utilization management solutions market size was estimated at USD 613.15 million in 2024 and is projected to grow to USD 1,200.90 million by 2030. For drug utilization management specifically, the U.S. market size was estimated at USD 39.77 billion in 2024 and is projected to reach USD 75.79 billion by 2033.
- Medical Case Management Services: The market size of Medical Case Management Services in the U.S. was $20.3 billion in 2024 and $21.0 billion in 2025. The global medical case management market, where North America holds a significant share, was valued at USD 5.73 billion in 2024 and is projected to reach USD 8.95 billion by 2034.
AI Analysis | Feedback
CorVel (CRVL) is expected to drive future revenue growth over the next 2-3 years through a combination of technological advancements, strategic market expansion, and enhanced client engagement.
Here are 3-5 expected drivers of future revenue growth:
* **Continued Investment and Integration of AI and Automation.** CorVel is significantly investing in artificial intelligence (AI) and automation across its products, services, and software development. These initiatives are aimed at augmenting operations, improving efficiency, enhancing client outcomes, reducing service delivery costs, and accelerating software development. The company anticipates these investments will drive cost efficiencies and potential margin expansion, leading to more competitive offerings and improved service quality that attracts and retains clients.
* **Expansion of Product Offerings and Service Lines, Including Strategic Acquisitions.** CorVel remains focused on expanding its technology roadmap for 2026, leveraging its debt-free balance sheet to support strategic product expansion. The company has seen growth in various network solutions and patient management services, including Independent Medical Evaluations, CERIS, Ancillary Care Solutions, Medical Bill Re-review, and Claims Management. Additionally, a strategic acquisition of assets and key talent from a privately held technology firm in June 2025 is contributing to increased efficiency in health payment integrity services and expanding AI capabilities.
* **Growth in Customer Base and Deeper Engagement with Existing Clients.** CorVel is focused on expanding business with existing partners and securing new business opportunities. The company has a reported net revenue retention rate of 100% across the business and a 44% close rate on new business opportunities. Strategic initiatives also include the pursuit of municipal and large corporate accounts and strategic insurer partnerships.
* **Increased Adoption of Third-Party Administrator (TPA) Services.** Forecasts suggest that CorVel is on track to surpass $1 billion in annual revenue by the end of 2027, provided the current adoption rates for its TPA services continue. This indicates a significant expected growth driver in this segment.
* **Scaling Medicare Secondary Payer (MSP) Compliance Services.** As part of its 2026 plan, CorVel prioritizes scaling its Medicare Secondary Payer compliance services. This addresses the rising regulatory complexity for long-term settlements, especially within an aging workforce, indicating a targeted market expansion for this specific service.
AI Analysis | Feedback
Share Repurchases
- CorVel has an ongoing and aggressive share repurchase program. For the nine months ending December 2025, the company repurchased 185,559 shares at a cost of $13.4 million.
- As of December 2025, CorVel had repurchased 69% of its total shares outstanding since the program's inception, with an aggregated total cost of $868 million (or $886.61 million as of February 2026).
- As of March 31, 2025, the company had 2,523,309 shares authorized for future repurchase remaining under its program.
Share Issuance
- In December 2024, CorVel executed a three-for-one stock split to enhance the accessibility of its shares for a broader range of investors.
Outbound Investments
- CorVel completed a "small technology-centric acquisition" in June 2025, which has been integrated into its health payment integrity business to improve efficiency and accelerate its product roadmap.
- The company's strategy includes mergers and acquisitions to expand service offerings and bolster its technology expertise.
Capital Expenditures
- For the nine months ending December 2025, capital expenditures amounted to $36 million, an increase from $24 million to $27 million in the same period of the prior fiscal year.
- The primary focus of these capital expenditures is increased spending on proprietary software development and software licenses related to AI and technology investments.
- Management plans to continue these investments in AI and technology to drive future profitability and efficiency gains.
Peer Outperformance in Health Care Services
CRVL has outperformed 63% of its 19 Health Care Services peers over 5Y. Among the peers that beat it are RDNT, DGX and ADUS. Health Care Services ranks 3rd of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.
Share of Health Care Services constituents that CRVL has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
14%
of 21 industry peers · -8.5% return
3Y
32%
of 19 industry peers · 15.3% return
5Y
63%
of 19 industry peers · 17.8% return
Health Care Services peers with revenue growth within 4pp of CRVL's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| CRVL | CorVel | 10.4% | 32.3x | -8.5% | 15.3% | 17.8% | — |
| RDNT | RadNet | 14.1% | -269.7x | -5.2% | 165.2% | 150.5% | +133pp |
| DGX | Quest Diagnostics | 7.0% | 24.4x | 26.8% | 100.1% | 67.7% | +50pp |
| ADUS | Addus HomeCare | 13.9% | 20.0x | 0.2% | 34.1% | 38.4% | +21pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Services is CRVL's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 11.6% | 44.3% | 89.1% | CAH 382% · MCK 344% · COR 169% |
| Managed Health Care | 8 | 33.1% | -7.9% | -0.7% | OSCR 80% · HQY 37% · ELV 12% |
| Health Care Services ← | 20 | 18.1% | 34.7% | -2.4% | HIMS 250% · RDNT 151% · DGX 68% |
| Health Care Facilities | 24 | 5.4% | 11.5% | -4.7% | NHC 271% · THC 259% · ENSG 135% |
| Health Care Equipment | 50 | -1.9% | -1.3% | -20.7% | POCI 11788% · UFPT 362% · GKOS 203% |
| Health Care Supplies | 12 | 20.3% | -6.4% | -38.9% | LNTH 271% · HAE 54% · MMSI 20% |
| Pharmaceuticals | 63 | -9.2% | 9.6% | -40.4% | LQDA 2252% · INDV 1097% · ETON 1010% |
| Life Sciences Tools & Services | 113 | 4.7% | -9.1% | -68.4% | SNWV 1820% · NTRA 231% · MEDP 211% |
| Health Care Technology | 21 | -26.8% | -50.0% | -78.6% | SPOK 71% · HSTM 1% · VEEV -10% |
| Biotechnology | 378 | -4.0% | -21.9% | -79.0% | CELZ 1291% · DNTH 1151% · ELVN 997% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| 6-Day Rally Sends CorVel Stock Up 16% | 08/20/2026 | |
| CorVel Stock Slides 26% In A Single Day, Should You Buy The Stock? | 02/04/2026 | |
| Would You Still Hold CorVel Stock If It Fell Another 30%? | 02/04/2026 | |
| CorVel Earnings Notes | 12/27/2025 | |
| CorVel vs Microsoft: Which Is A Better Investment? | 08/18/2025 | |
| CorVel vs Eli Lilly: Which Is A Better Investment? | 08/18/2025 | |
| Better Bet Than CRVL Stock: Pay Less Than CorVel To Get More From META, LLY | 08/12/2025 | |
| Better Bet Than CRVL Stock: Pay Less Than CorVel To Get More From LLY, BMRN | 08/12/2025 | |
| ARTICLES | ||
| A 6-Day Winning Streak Has CorVel Stock Up 16% | 08/20/2026 | |
| Buy or Sell CorVel Stock? | 02/04/2026 | |
| CorVel Stock Drop Looks Sharp, But How Deep Can It Go? | 02/04/2026 | |
| Stocks Trading At 52-Week Low | 09/16/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 248.95 |
| Mkt Cap | 64.7 |
| Rev LTM | 108,434 |
| Op Inc LTM | 2,691 |
| FCF LTM | 4,287 |
| FCF 3Y Avg | 3,173 |
| CFO LTM | 4,956 |
| CFO 3Y Avg | 3,843 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.8% |
| Rev Chg 3Y Avg | 9.6% |
| Rev Chg Q | 4.0% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Inc Chg LTM | 2.4% |
| Op Inc Chg 3Y Avg | 15.5% |
| Op Mgn LTM | 6.1% |
| Op Mgn 3Y Avg | 6.8% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 7.0% |
| CFO/Rev 3Y Avg | 5.8% |
| FCF/Rev LTM | 5.3% |
| FCF/Rev 3Y Avg | 3.9% |
Price Behavior
Price Behavior
| Market Price | $73.30 | |
| Market Cap ($ Bil) | 3.7 | |
| First Trading Date | 06/28/1991 | |
| Distance from 52W High | -8.5% | |
| 50 Days | 200 Days | |
| DMA Price | $66.00 | $61.37 |
| DMA Trend | down | up |
| Distance from DMA | 11.1% | 19.4% |
| 3M | 1YR | |
| Volatility | 29.5% | 41.5% |
| Downside Capture | -97.28 | 18.18 |
| Upside Capture | 7.70 | 4.56 |
| Correlation (SPY) | -23.6% | 0.9% |
CRVL Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.57 | -0.69 | -0.63 | -0.31 | 0.04 | 0.61 |
| Up Beta | -1.73 | -2.24 | -1.46 | -0.69 | -0.29 | 0.71 |
| Down Beta | 1.02 | -0.26 | 0.00 | -0.21 | 0.09 | 0.40 |
| Up Capture | 95% | 9% | -27% | 11% | -2% | 27% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 20 | 33 | 69 | 123 | 367 |
| Down Capture | -218% | -58% | -106% | -80% | 43% | 91% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 22 | 31 | 58 | 128 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRVL | |
|---|---|---|---|---|
| CRVL | -7.8% | 41.4% | -0.08 | - |
| Sector ETF (XLV) | 25.2% | 16.1% | 1.20 | 21.6% |
| Equity (SPY) | 16.2% | 13.0% | 0.88 | 0.9% |
| Gold (GLD) | 13.9% | 29.3% | 0.44 | -19.7% |
| Commodities (DBC) | 46.6% | 20.7% | 1.75 | -10.6% |
| Real Estate (VNQ) | 4.5% | 13.7% | 0.08 | 17.4% |
| Bitcoin (BTCUSD) | -23.2% | 44.8% | -0.46 | 4.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRVL | |
|---|---|---|---|---|
| CRVL | 5.6% | 33.5% | 0.22 | - |
| Sector ETF (XLV) | 6.6% | 15.2% | 0.25 | 36.5% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 34.4% |
| Gold (GLD) | 18.6% | 18.8% | 0.80 | -6.5% |
| Commodities (DBC) | 10.5% | 19.5% | 0.41 | -0.6% |
| Real Estate (VNQ) | 0.8% | 18.9% | -0.06 | 35.5% |
| Bitcoin (BTCUSD) | 12.5% | 52.6% | 0.41 | 18.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRVL | |
|---|---|---|---|---|
| CRVL | 19.4% | 34.4% | 0.61 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 44.9% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 46.9% |
| Gold (GLD) | 12.1% | 16.4% | 0.60 | -3.4% |
| Commodities (DBC) | 8.5% | 18.1% | 0.38 | 10.6% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 44.6% |
| Bitcoin (BTCUSD) | 64.2% | 66.2% | 1.04 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -0.2% | 0.3% | 9.8% |
| 5/20/2026 | -4.2% | -4.1% | -10.4% |
| 2/3/2026 | -4.8% | -9.7% | 6.3% |
| 11/4/2025 | -0.8% | 2.0% | -9.1% |
| 8/5/2025 | 0.8% | 2.5% | -1.9% |
| 5/22/2025 | -3.7% | -2.9% | -8.6% |
| 2/4/2025 | 7.5% | 1.2% | -7.1% |
| 11/5/2024 | 11.0% | 13.7% | 11.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 11 |
| # Negative | 15 | 13 | 13 |
| Median Positive | 1.9% | 2.5% | 6.5% |
| Median Negative | -1.8% | -4.1% | -5.3% |
| Max Positive | 11.0% | 13.7% | 11.3% |
| Max Negative | -6.7% | -14.3% | -11.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -0.2% | 0.3% | 9.8% |
| 5/20/2026 | -4.2% | -4.1% | -10.4% |
| 2/3/2026 | -4.8% | -9.7% | 6.3% |
| 11/4/2025 | -0.8% | 2.0% | -9.1% |
| 8/5/2025 | 0.8% | 2.5% | -1.9% |
| 5/22/2025 | -3.7% | -2.9% | -8.6% |
| 2/4/2025 | 7.5% | 1.2% | -7.1% |
| 11/5/2024 | 11.0% | 13.7% | 11.3% |
| 7/30/2024 | -4.1% | -7.7% | -1.7% |
| 5/22/2024 | -1.6% | -14.3% | -11.4% |
| 1/30/2024 | -0.8% | -2.0% | 2.8% |
| 10/31/2023 | 0.5% | 2.0% | 7.7% |
| 8/1/2023 | 5.5% | 4.9% | 6.4% |
| 5/25/2023 | -2.9% | 1.4% | -3.2% |
| 1/31/2023 | 3.1% | 5.3% | 6.5% |
| 11/1/2022 | -1.8% | -7.3% | -3.4% |
| 8/2/2022 | -0.0% | -6.6% | -7.6% |
| 5/26/2022 | 0.6% | -3.9% | -4.2% |
| 2/1/2022 | -3.9% | -14.1% | -5.3% |
| 11/2/2021 | -0.1% | 2.7% | 5.1% |
| 8/3/2021 | -0.2% | -0.5% | 8.0% |
| 5/27/2021 | 0.8% | -3.7% | 7.2% |
| 2/2/2021 | 1.9% | 5.6% | 1.8% |
| 11/3/2020 | -6.7% | -2.9% | -0.3% |
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 11 |
| # Negative | 15 | 13 | 13 |
| Median Positive | 1.9% | 2.5% | 6.5% |
| Median Negative | -1.8% | -4.1% | -5.3% |
| Max Positive | 11.0% | 13.7% | 11.3% |
| Max Negative | -6.7% | -14.3% | -11.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/22/2026 | 10-K |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/23/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/24/2024 | 10-K |
| 12/31/2023 | 02/01/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/26/2023 | 10-K |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/22/2026 | 10-K |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/23/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/24/2024 | 10-K |
| 12/31/2023 | 02/01/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/26/2023 | 10-K |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/27/2022 | 10-K |
| 12/31/2021 | 02/03/2022 | 10-Q |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/28/2021 | 10-K |
| 12/31/2020 | 02/04/2021 | 10-Q |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 06/10/2020 | 10-K |
| 12/31/2019 | 02/07/2020 | 10-Q |
| 09/30/2019 | 11/07/2019 | 10-Q |
Insider Activity
Updated 9/15/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corstar, Holdings Inc | Direct | Sell | 9152026 | 70.16 | 127,824 | 8,968,055 | 1,299,149,187 | Form | |
| 2 | Corstar, Holdings Inc | Direct | Sell | 9152026 | 69.05 | 30,925 | 2,135,303 | 1,287,391,536 | Form | |
| 3 | Corstar, Holdings Inc | Direct | Sell | 9082026 | 68.76 | 14,538 | 999,573 | 1,284,075,356 | Form | |
| 4 | Corstar, Holdings Inc | Direct | Sell | 9082026 | 68.91 | 51,713 | 3,563,605 | 1,287,977,548 | Form | |
| 5 | Jessup, R Judd | Direct | Sell | 9032026 | 70.07 | 4,023 | 281,892 | 7,833,686 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corstar, Holdings Inc | Direct | Sell | 9152026 | 70.16 | 127,824 | 8,968,055 | 1,299,149,187 | Form | |
| 2 | Corstar, Holdings Inc | Direct | Sell | 9152026 | 69.05 | 30,925 | 2,135,303 | 1,287,391,536 | Form | |
| 3 | Corstar, Holdings Inc | Direct | Sell | 9082026 | 68.76 | 14,538 | 999,573 | 1,284,075,356 | Form | |
| 4 | Corstar, Holdings Inc | Direct | Sell | 9082026 | 68.91 | 51,713 | 3,563,605 | 1,287,977,548 | Form | |
| 5 | Jessup, R Judd | Direct | Sell | 9032026 | 70.07 | 4,023 | 281,892 | 7,833,686 | Form | |
| 6 | Jessup, R Judd | Direct | Sell | 8282026 | 70.64 | 1,262 | 89,148 | 8,181,595 | Form | |
| 7 | Jessup, R Judd | Direct | Sell | 8282026 | 70.71 | 1,562 | 110,449 | 8,278,939 | Form | |
| 8 | Yoss, Jennifer | Vice President of Accounting | Direct | Sell | 8242026 | 70.92 | 2,100 | 148,922 | 154,098 | Form |
| 9 | Shishin, Maxim | Chief Information Officer | Direct | Sell | 6152026 | 60.59 | 2,250 | 136,328 | 427,160 | Form |
| 10 | Combs, Michael G | CEO & President | Direct | Sell | 6152026 | 60.79 | 500 | 30,395 | 749,054 | Form |
| 11 | Combs, Michael G | CEO & President | Direct | Sell | 6112026 | 60.55 | 7,000 | 423,820 | 776,317 | Form |
| 12 | Combs, Michael G | CEO & President | Direct | Sell | 6112026 | 61.38 | 7,000 | 429,626 | 1,216,577 | Form |
| 13 | Combs, Michael G | CEO & President | Direct | Sell | 6112026 | 60.90 | 7,000 | 426,293 | 1,633,433 | Form |
| 14 | Michael, Jeffrey J | Direct | Sell | 6102026 | 60.98 | 9,000 | 548,834 | 34,132,682 | Form | |
| 15 | Combs, Michael G | CEO & President | Direct | Sell | 6092026 | 60.22 | 7,000 | 421,558 | 2,036,849 | Form |
| 16 | Yoss, Jennifer | Vice President of Accounting | Direct | Sell | 5272026 | 61.02 | 1,999 | 121,980 | 132,598 | Form |
| 17 | Shishin, Maxim | Chief Information Officer | Direct | Sell | 3172026 | 54.00 | 2,400 | 129,604 | 380,711 | Form |
| 18 | Combs, Michael G | CEO & President | Direct | Sell | 3102026 | 54.00 | 8,013 | 432,702 | 2,201,040 | Form |
| 19 | Hamerslag, Steven J | Direct | Sell | 2172026 | 48.41 | 10,000 | 484,100 | 13,893,670 | Form | |
| 20 | Hamerslag, Steven J | Direct | Sell | 2172026 | 47.17 | 10,000 | 471,700 | 14,009,490 | Form | |
| 21 | Jessup, R Judd | Direct | Sell | 11242025 | 76.20 | 3,247 | 247,421 | 8,519,008 | Form | |
| 22 | Bertels, Mark E | EVP - Risk Management Services | Direct | Sell | 11202025 | 72.35 | 1,200 | 86,820 | 187,676 | Form |
| 23 | Jessup, R Judd | Direct | Sell | 11122025 | 76.94 | 7,076 | 544,427 | 8,851,562 | Form | |
| 24 | Jessup, R Judd | Direct | Sell | 11122025 | 76.27 | 210 | 16,017 | 9,314,169 | Form | |
| 25 | Shishin, Maxim | Chief Information Officer | Direct | Sell | 9122025 | 87.82 | 18,000 | 1,580,823 | 619,156 | Form |
| 26 | Corstar, Holdings Inc | Direct | Sell | 9102025 | 91.46 | 70,000 | 6,402,200 | 1,714,153,198 | Form | |
| 27 | O'Brien, Brandon | Chief Financial Officer | Direct | Sell | 9102025 | 91.54 | 1,764 | 161,471 | 819,070 | Form |
| 28 | Corstar, Holdings Inc | Direct | Sell | 9022025 | 88.85 | 40,000 | 3,553,920 | 1,671,418,172 | Form |
Investor Activity (13F)
Updated Sep 24, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/23/2026